Switch theme
Sign up to access all valuation multiples
Caliway Biopharmaceuticals Co Ltd specializes in the development of new drugs for aesthetic medicine and chronic inflammation. Its pipeline candidates are CBL-514, CBA-539, and CBO-012.
2012
n/a
LTM Revenue $84.2M
LTM EBITDA $52.6M
$4.2B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Caliway Biopharmaceuticals has a last 12-month revenue (LTM) of $84.2M and a last 12-month EBITDA of $52.6M.
In the most recent fiscal year, Caliway Biopharmaceuticals achieved revenue of $1.5M and an EBITDA of -$18.6M.
Caliway Biopharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Caliway Biopharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $84.2M | XXX | $1.5M | XXX | XXX | XXX |
| Gross Profit | $83.7M | XXX | $1.0M | XXX | XXX | XXX |
| Gross Margin | 99% | XXX | 69% | XXX | XXX | XXX |
| EBITDA | $52.6M | XXX | -$18.6M | XXX | XXX | XXX |
| EBITDA Margin | 63% | XXX | -1258% | XXX | XXX | XXX |
| EBIT | $51.7M | XXX | -$23.9M | XXX | XXX | XXX |
| EBIT Margin | 61% | XXX | -1614% | XXX | XXX | XXX |
| Net Profit | $7.8M | XXX | -$19.6M | XXX | XXX | XXX |
| Net Margin | 9% | XXX | -1325% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | n/a | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Caliway Biopharmaceuticals's stock price is TWD 877 (or $29).
Caliway Biopharmaceuticals has current market cap of TWD 136B (or $4.5B), and EV of TWD 126B (or $4.2B).
See Caliway Biopharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $4.2B | $4.5B | XXX | XXX | XXX | XXX | $0.06 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Caliway Biopharmaceuticals has market cap of $4.5B and EV of $4.2B.
Caliway Biopharmaceuticals's trades at 2836.8x EV/Revenue multiple, and -225.5x EV/EBITDA.
Equity research analysts estimate Caliway Biopharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Caliway Biopharmaceuticals has a P/E ratio of 576.8x.
See valuation multiples for Caliway Biopharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $4.5B | XXX | $4.5B | XXX | XXX | XXX |
| EV (current) | $4.2B | XXX | $4.2B | XXX | XXX | XXX |
| EV/Revenue | 50.0x | XXX | 2836.8x | XXX | XXX | XXX |
| EV/EBITDA | 79.9x | XXX | -225.5x | XXX | XXX | XXX |
| EV/EBIT | 81.4x | XXX | -175.8x | XXX | XXX | XXX |
| EV/Gross Profit | 50.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | 576.8x | XXX | -230.3x | XXX | XXX | XXX |
| EV/FCF | 96.9x | XXX | -236.3x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialCaliway Biopharmaceuticals's last 12 month revenue growth is 233%
Caliway Biopharmaceuticals's revenue per employee in the last FY averaged n/a, while opex per employee averaged n/a for the same period.
Caliway Biopharmaceuticals's rule of 40 is -949% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Caliway Biopharmaceuticals's rule of X is 644% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Caliway Biopharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 233% | XXX | 1525% | XXX | XXX | XXX |
| EBITDA Margin | 63% | XXX | -1258% | XXX | XXX | XXX |
| EBITDA Growth | 360% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -949% | XXX | -1025% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | 644% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | n/a | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 1463% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 1683% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Caliway Biopharmaceuticals acquired XXX companies to date.
Last acquisition by Caliway Biopharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Caliway Biopharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Caliway Biopharmaceuticals founded? | Caliway Biopharmaceuticals was founded in 2012. |
| Where is Caliway Biopharmaceuticals headquartered? | Caliway Biopharmaceuticals is headquartered in Taiwan. |
| Is Caliway Biopharmaceuticals publicy listed? | Yes, Caliway Biopharmaceuticals is a public company listed on TAI. |
| What is the stock symbol of Caliway Biopharmaceuticals? | Caliway Biopharmaceuticals trades under 6919 ticker. |
| When did Caliway Biopharmaceuticals go public? | Caliway Biopharmaceuticals went public in 2022. |
| Who are competitors of Caliway Biopharmaceuticals? | Similar companies to Caliway Biopharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Caliway Biopharmaceuticals? | Caliway Biopharmaceuticals's current market cap is $4.5B |
| What is the current revenue of Caliway Biopharmaceuticals? | Caliway Biopharmaceuticals's last 12 months revenue is $84.2M. |
| What is the current revenue growth of Caliway Biopharmaceuticals? | Caliway Biopharmaceuticals revenue growth (NTM/LTM) is 233%. |
| What is the current EV/Revenue multiple of Caliway Biopharmaceuticals? | Current revenue multiple of Caliway Biopharmaceuticals is 50.0x. |
| Is Caliway Biopharmaceuticals profitable? | Yes, Caliway Biopharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Caliway Biopharmaceuticals? | Caliway Biopharmaceuticals's last 12 months EBITDA is $52.6M. |
| What is Caliway Biopharmaceuticals's EBITDA margin? | Caliway Biopharmaceuticals's last 12 months EBITDA margin is 63%. |
| What is the current EV/EBITDA multiple of Caliway Biopharmaceuticals? | Current EBITDA multiple of Caliway Biopharmaceuticals is 79.9x. |
| What is the current FCF of Caliway Biopharmaceuticals? | Caliway Biopharmaceuticals's last 12 months FCF is $43.4M. |
| What is Caliway Biopharmaceuticals's FCF margin? | Caliway Biopharmaceuticals's last 12 months FCF margin is 52%. |
| What is the current EV/FCF multiple of Caliway Biopharmaceuticals? | Current FCF multiple of Caliway Biopharmaceuticals is 96.9x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
